NIH R01 · 2024
First in Human Study of a Tau Self-Association Small Molecule Inhibitor in Healthy Volunteers
PROJECT SUMMARY This program is focused on developing a disease-modifying drug for Alzheimer’s disease (AD) by advancing our lead compound into clinical development. There are no disease-modifying small molecule drugs for AD, and the prevalence of AD is increasing worldwide. This program is progressing to fill this need with a disease modifying drug that, if successful, will have a tremendous impact on the more than 6.7 million Americans who currently have AD (projected to be 13.8 million by 2060) and their caregivers, and will help reduce the current cost of $345 billion (projected to be $1.1 trillion by 2050) to our nation (Alzheimer's Association 2023 Alzheimer's Disease Facts and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.